Drug Discovery World

JANUARY 27, 2023

Cell and gene therapies have been making the news this week, as we launch our very own guide to global innovation in CGT with the Winter issue of DDW, as well as an exciting new virtual event on the same topic. The post This week in drug discovery (23-27 January) appeared first on Drug Discovery World (DDW).

RNA 130

RNA Drugs Therapies Virus 130

The Pharma Data

DECEMBER 10, 2020

The conference was held in the early days of the outbreak, even before most people knew of the dangers of the virus and certainly before mask wearing and social distancing was recommended. It was initially reported that three Biogen employees who attended that meeting had tested positive for the virus.

Virus 52

Virus Hospitals Research Science 52

Drug Discovery World

FEBRUARY 5, 2024

Opening keynote Following a change to the schedule, Juliet Williams of Kymera Therapeutics launched the event with a popular keynote talk ‘Solving Big Problems with Small Molecule Degraders’. Product launches More than 400 exhibitors are at the event this year, many of whom are launching new products.

Small Molecule 162

Small Molecule Assay Development Production Science 162

Drug Discovery World

AUGUST 9, 2023

A new respiratory syncytial virus (RSV) vaccine candidate has achieved positive safety and immunogenicity results in a Phase I clinical study of RSV-naïve participants between the ages of six and 36 months. MV-012-968 is being developed by Meissa Vaccines as a needle-free, adjuvant-free vaccine to protect infants and toddlers from RSV.

Vaccine 130

Vaccine Virus Disease Drugs 130

Drug Discovery World

DECEMBER 19, 2022

Researchers have found that a topical gene therapy gel helps heal wounds in patients with life-threatening blistering skin disease epidermolysis bullosa (EB). . This was a life-changing event for Vincenzo,” said Peter Marinkovich, Associate Professor of Dermatology and Director of Stanford Medicine’s Blistering Disease Clinic.

Therapies 130

Therapies Clinical Trials Trials Virus 130

Drug Discovery World

FEBRUARY 24, 2023

New Covid-19 booster outperforms approved vaccines Covid-19 booster candidate UB-612 has achieved its immunogenicity endpoints in a head-to-head trial against three vaccine platforms: mRNA (Pfizer-BioNTech’s BNT162b2), adenovirus vector (AstraZeneca’s ChAdOx1-S), and inactivated virus (Sinopharm’s BIBP).

Vaccine 130

Vaccine Drugs Clinical Trials Virus 130

Drug Discovery World

JANUARY 22, 2024

At this year’s SLAS event, DDW has curated a track taking place in the Ignite Theater. Masaru Kanekiyo , Chief of Molecular Immunoengineering Section (MIS) of the Vaccine Research Center (VRC) at the US National Institute of Allergy and Infectious Diseases (NIAID), will present ‘Structural vaccinology for influenza’.

Vaccine 147

Vaccine Immune Response Engineering Virus 147

Drug Discovery World

AUGUST 30, 2022

It limits viral spread in the body by inhibiting the work of the protein involved in the release of the enveloped virus. Recently, the Centers for Disease Control and Prevention (CDC) allowed physicians to prescribe tecovirimat on a compassionate use basis to treat adults and children with orthopoxvirus infections, including monkeypox.

Therapies 130

Therapies FDA Approval Vaccine Treatment 130

Drug Discovery World

OCTOBER 13, 2022

DDW’s Megan Thomas comments on the presentations, posters and booths at the event and the new addition of the ELRIG Tech Theatre, supported by DDW. . When it comes to metrics of success for an event such as Drug Discovery 2022, the numbers speak for themselves. Over the two days at ExCel, 1554 delegates attended the event.

Drugs 130

Drugs Cell Based Assays Science Assay Development 130

Drug Discovery World

JANUARY 21, 2024

Inspired by the overall event theme of ‘Innovation at Every Turn’, the DDW track will present leading research and case studies from experts in academia, government agencies and the industry on how technology is innovating from bench to bedside, lab to patient.

Vaccine 130

Vaccine Computational Chemistry Animal Testing Engineering 130

Drug Discovery World

APRIL 15, 2023

As the theme, Advancing the Frontiers of Cancer Science and Medicine , suggests, a number of announcements, results and presentations will take place at what is widely considered to be a flagship event for the cancer research community. Here are eight anticipated ‘curtain raisers’ in advance of the event: 1.

Virus 130

Virus Clinical Trials Trials Therapies 130

DrugBank

JULY 18, 2024

Vaccines have consistently demonstrated their efficacy in protecting people from infectious diseases. This led to the eradication of smallpox and polio – two debilitating diseases that historically caused global epidemics. Let’s take a deeper dive into these challenges.

Vaccine 79

Vaccine Immune Response Clinical Trials Virus 79

The Pharma Data

APRIL 26, 2022

NYSE: PFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15. No vaccine-related serious adverse events (SAEs) were observed. About VLA15 VLA15 is the only Lyme disease vaccine candidate currently in clinical development. The study is being conducted at U.S.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

Drug Discovery World

SEPTEMBER 14, 2023

Total revenue from oncology medicines increased 22%, CVRM 20%, R&I8 10%, and rare disease 12%. Additionally, Abrysvo was approved for use at 32-36 weeks gestational age of pregnancy to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants from birth to six months of age.

Vaccine 147

Vaccine FDA Approval Drugs Licensing 147

Advarra

JUNE 13, 2024

Known as oncolytic viruses, these are engineered to restrict replication and spread of the virus to within the tumor tissue, but the safeguards engineered for this purpose are not absolute (unlike those used to make viruses replication-incompetent). The SOP should list these symptoms and any available prophylaxis for post-exposure treatment.

Clinical Trials 52

Clinical Trials Engineering Trials Virus 52

Drug Discovery World

OCTOBER 4, 2022

This year’s event will cover some of the most exciting advancements in areas spanning screening, automation, high content imaging, disease models, cell and gene therapies and how innovation is being driven through partnerships and collaborations. Collaborations.

Drugs 130

Drugs Therapies Clinical Trials Cell Based Assays 130

The Pharma Data

OCTOBER 28, 2020

In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36 Serious adverse events were numerically more frequent with placebo than REGN-COV2 treatment (0.8% There was a 1.08 REGN-COV2 was well tolerated in the trial. high dose, 1.6% low dose; 2.3%

Virus 40

Virus Trials Clinical Trials Production 40

Drug Target Review

JANUARY 26, 2024

This binding triggers a cascade of events that leads to the fusion between cell and viral membranes enabling cell entry. These ACE2-coated particles could be tested as an anti-viral therapeutic, and as sensors for detecting virus particles.

Production 114

Production DNA Virus Protein Expression 114

Alta Sciences

JANUARY 11, 2024

It is estimated that there are over 6,000 monogenic diseases, affecting over 350 million people worldwide; for these diseases, cell and gene therapy may provide hope for a cure. There are three primary vectors employed in gene therapy: adeno-associated virus (AAV), adenovirus, or lentivirus vectors.

Therapies 52

Therapies Immune Response Virus Disease 52

PLOS: DNA Science

AUGUST 22, 2024

The Associated Press deemed Eruption “a seismic publishing event.” Unforgettably, my daughter Heather threw up on the volcano, an early sign of gallbladder disease and to this day, her claim to fame. Crichton authored 28 novels, Patterson more than 200. TMV is a common pathogen used in early molecular biology research.

DNA 52

DNA Virus Organic Chemistry Science 52

The Pharma Data

AUGUST 15, 2021

adults and children against the TBE virus when visiting or living in TBE endemic areas. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) is expected to discuss recommendations on the safe and appropriate use of TICOVAC. 1 TICOVAC is the only FDA-approved vaccine to help protect U.S.

FDA Approval 52

FDA Approval Vaccine FDA Virus 52

The Pharma Data

SEPTEMBER 1, 2021

MOVe-AHEAD (MK-4482-013) ( NCT04939428 ) is a Phase 3 multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of orally administered molnupiravir compared to placebo in preventing the spread of SARS-CoV-2, the virus that causes COVID-19, within households. MOVe-AHEAD Study. About Molnupiravir.

Laboratories 52

Laboratories Virus Clinical Trials Research Laboratories 52

Drug Target Review

SEPTEMBER 8, 2023

However, recent insights indicate that it also operates beyond the nucleus, orchestrating initial events at the cell surface that trigger the activation of T cells. Remarkably, these findings propose that the presence of a cytoplasmic version of RARα is indispensable for T cells to initiate their defence against diseases.

Regulations 98

Regulations Research DNA Immune Response 98

The Pharma Data

SEPTEMBER 5, 2021

Member States will be provided with regular delivery schedules, and capped rebates will apply in the event of any delayed doses. In clinical trials, Vaxzevria demonstrated 100% efficacy against severe disease and hospitalisation after two doses. To date, AstraZeneca and its partners have supplied more than 1.1

Vaccine 52

Vaccine Virus Clinical Trials Trials 52

The Pharma Data

JULY 28, 2021

Incidence of very rare thromboembolic events was far lower than in people diagnosed with COVID-19 infection. 1 Follow-up time was not sufficient to report rates after two doses of Vaxzevria , though other studies have shown rates of rare blood clotting events to be lower after a second dose.

Vaccine 52

Vaccine Virus Science Production 52

The Pharma Data

MARCH 8, 2021

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. About Molnupiravir.

Trials 69

Trials Virus RNA Research Laboratories 69

Codon

JANUARY 21, 2024

Today, refined versions of these human challenge studies have become standard practice in testing vaccines for vector-borne diseases (e.g., yellow fever, malaria, and dengue), evaluating new drugs or treatments, and studying pathogenesis, the process by which a disease develops. How are disease targets selected for challenge trials?

Vaccine 111

Vaccine Trials Disease Virus 111

The Pharma Data

MARCH 22, 2021

100% efficacy against severe or critical disease and hospitalisation. The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalisation. Favourable reactogenicity and overall safety profile.

Trials 52

Trials Vaccine Virus Disease 52

Drug Discovery World

FEBRUARY 13, 2023

Meanwhile, Poolbeg Pharma and OneThree Biotech have discovered novel drug targets for the treatment of respiratory syncytial virus (RSV) using an AI programme. While companies make these commitments and partner for a better future, others shared successes in 2022.

Protein Production 130

Protein Production DNA Virus Vaccine 130

The Pharma Data

JULY 28, 2021

The analysis was conducted using AstraZeneca’s global safety database, which captures all spontaneously reported adverse events from real-world use of its medicines and vaccines worldwide. Furthermore, these very rare events can be avoided when symptoms are identified and treated appropriately.

Vaccine 52

Vaccine Virus Science Production 52

Drug Discovery World

NOVEMBER 1, 2022

Additionally, no drug related serious adverse events have been observed. . This combination therapy escalation arm will then expand at the recommended Phase II dose level and further evaluate the potential efficacy of Auceliciclib in improving patient outcomes for this difficult to treat disease. Ground-breaking therapies .

Drugs 130

Drugs Science Therapies Clinical Trials 130

Advarra

MARCH 31, 2023

This trend came to the forefront during the COVID-19 pandemic, as the three most popular vaccines developed in response to the coronavirus contained engineered genetic materials in the form of mRNA or a genetically engineered virus. A key part of the IBC’s evaluation is assessing the risks posed by the engineered genetic materials.

Engineering 52

Engineering Clinical Research Research Virus 52

The Pharma Data

NOVEMBER 9, 2021

Among the populations most significantly affected by COVID-19 are the elderly and patients with preexisting medical conditions including diabetes, hypertension, obesity, metabolic syndrome, cardiovascular disease and chronic lung diseases like COPD and asthma. What’s more, chitinase 3-like-1 augments SARS CoV-2 infection.”

Small Molecule 52

Small Molecule Virus Molecular Biology Disease 52

The Pharma Data

JANUARY 8, 2021

While speaking at a virtual event hosted by Oddo BHF, a financial service group, Bancel said the “nightmare scenario” that the vaccine will not work is now in the past. FRIDAY, Jan. 8, 2021 — Moderna CEO Stéphane Bancel said the company’s COVID-19 vaccine may prevent infection for years, CBS News reported Thursday.

Vaccine 52

Vaccine Virus Disease 52

The Pharma Data

JANUARY 29, 2021

(MedMira) (TSXV: MIR) announces the development of a rapid antibody test prototype that detects the presence of the neutralizing antibodies against the SARS-CoV-2 virus. About MedMira. MedMira is a leading developer and manufacturer of Rapid Vertical Flow ® diagnostics.

Production 52

Production Virus Hospitals Vaccine 52

The Pharma Data

JANUARY 17, 2021

The treatment could be administered in primary care centers to people who test positive for COVID-19, avoiding hospitalization due to the progression of the disease and complementing the vaccine in the early phase after vaccination. BARCELONA, Spain , Jan. 18, 2021 /PRNewswire/ — Grifols (MCE: GRF, MCE: GRF.P,

Clinical Trials 52

Clinical Trials Treatment Trials Hospitals 52

The Pharma Data

DECEMBER 3, 2020

No serious adverse events related to the vaccine candidates studied were reported. The majority of adverse events were mild and transient. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope.

Vaccine 52

Vaccine Immune Response Virus RNA 52